Vyriad closed a $25 million final tranche of a Series B financing, bringing the round to $85 million to fund first‑in‑human testing of VV‑169, an in vivo CAR‑T candidate for relapsed or refractory multiple myeloma. The financing positions Vyriad to transition its viral vector‑based in vivo CAR‑T platform into clinical evaluation, aiming to reduce manufacturing complexity compared with ex vivo CAR‑T. Company filings and the financing announcement detail investor participation and development milestones.